Boston Scientific wins big book as Bayer brings hybrid

By Mike Turner
06 Nov 2019

Boston Scientific Corp, the US medical devices maker, obtained plenty of demand for its €900m bond as it made its debut in the Reverse Yankee market on Wednesday, while the euro corporate bond pipeline continues to fill for a flurry of issuance in November.

Bank of America, Barclays, and Goldman Sachs were bookrunners, and set initial price talk at 95bp over mid-swaps for the eight year issue rated Baa2/BBB-/BBB.

Demand swelled to more than €3bn and guidance was set at 75bp to 80bp. 

The bond was then priced at the tight end of guidance ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access:

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: or find out more online here.